anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine. ^ SUBSTANCE: invention relates to veterinary. Veterinary composition for prevention and treatment of various form of endometritis contains propanol in combination with antibacterial component, water polymers of polysaccharide class, mixture of fat-soluble vitamins A, D and E and pharmaceutically suitable solvent, as antibacterial component used is either antibiotic, selected from group of macrolides, aminoglycosides, polypeptides, linkosamides, cephalosporins, or sulfanilamide, or antiseptic, selected from group, including benzalkonium chloride, benzethonium chloride, nipagin, nirasol or their combination. Veterinary medication for prevention and treatment of various form of endometritis contains claimed composition and can represent solution or suspension for intrauterine introduction. ^ EFFECT: invention ensures increase of treatment efficiency. ^ 9 cl, 6 tbl, 5 ex
A tampon or wad for use in medical practice comprises a mass of fibres or fibrous material which is soluble in water or body fluids loaded with an ion-exchange agent or a mixture of ion-exchange agents adapted to modify the chemical characteristics of a liquid in an area to which the tampon or wad is applied.  The mixture may be of anion exchanger and cation exchanger in predetermined proportions. Particles of ion-exchange resin or natural ion-exchange material, which may be in a moist and expanded condition, are sprayed on to a thin layer of, e.g., water-soluble alginate or cellulose ether fibres, or both.  The layer may then be cut into sections and rolled or wrapped in a covering, e.g. a film of water-soluble material. Alternatively a covering for a tampon or wad may be formed by evaporating water from a gelatinous film, e.g., cellulose ether, on to which granules of ion-exchange material have previously been dusted or sprayed.  The dried film is used as a covering for a mass of water-soluble fibrous material, optionally impregnated with an ion-exchange agent, to form a tampon or wad.  The product may be used to eliminate the calcium ion with marked biological effects. Specification 722,629, [Group VI], is referred to.ALSO:A tampon or wad for use in medical or surgical practice comprises a mass of fibres or fibrous material which is soluble in water or body fluids loaded with one or more ion-exchange agents adapted to modify the chemical characteristics of a liquid in an area to which the tampon or wad is applied.  The agent may be a mixture in predetermined proportions of an anion-exchanger and a cation-exchanger.  Particles of ion-exchange resin or natural ion-exchange material, which may be in a moist and expanded condition, are sprayed onto a thin layer of, e.g., water-soluble alginate or cellulose ether fibres, or both.  The layer may then be cut into sections and rolled or wrapped in a covering, e.g. a film of water-soluble material.  Alternatively a covering for a tampon or wad may be formed by evaporating water from a gelatinous film of, e.g., cellulose ether, onto which granules of ion-exchange material have previously been dusted or sprayed.  The dried film is used as a covering for a mass of water-soluble fibrous material, optionally impregnated with an ion-exchange agent, to form a tampon or wad.  When the material is applied to the human body and comes into contact with any body fluid the insoluble particles of ion-exchange material will be adequately suspended in and subsequently carried away from the body area of use in the gelatinous mass to which the soluble fibres have expanded.  The material may be used as a temporary filling in a tooth cavity where by eliminating decay organisms it can prevent further decay.  According to the Provisional Specification filter pads or papers comprising insoluble fibres incorporating ion-exchange material may be used for removing calcium from milk to aid digestion or for removing sodium from broth without removing therefrom the taste of common salt of which the sodium forms part.  Specification 722,629 is referred to.
The control group will receive the same conventional program (as the experimental group) consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing. Ice will be applied to the ankle for 15 minutes at the end of each of the 8 sessions.
Trabeculectomy is the most common operation performed for all forms of glaucoma. The procedure depends upon appropriately modulated healing of the conjunctiva and sclera, a major component of which is delivery of frequent topical corticosteroid eye drops (prednisolone acetate 1%) by the patient, initially every 2 hours when awake for 1-2 weeks, then in tapering frequency over the 6 weeks after surgery. While the initial success of trabeculectomy at one year varies from 55-80% depending upon the criteria chosen to measure outcome, improvements in success would benefit hundreds of thousands of patients in the USA yearly. There is reasonable evidence that steroid drops benefit success, but there is essentially no data on how successfully patients remember to take the drops. In previous research, investigators have shown that glaucoma patients take only half to two-thirds of prescribed drops. An electronic monitoring device is now available that can fit the eye drop bottle used in steroid drops, accurately measuring the time and date of each drop taken. The investigators can further assess the accuracy with which each patient can deliver a drop from the bottle being monitored in a clinic session directly onto the eye's surface by observing their performance. The proposal's hypothesis is that the one year success rate of the procedure will be related to the adherence to steroid drop taking by patients. The outcome will have two important benefits. First, if adherence is less than ideal (which is very likely), then those with greater adherence will have more successful surgery, confirming that steroid treatment is effective. This has only been measured once, 30 years ago, at a time when trabeculectomy was being performed quite differently. If steroid treatment is not related to success, a change in preferred practice patterns is in order. If steroid treatment is related to success and adherence is variable, the investigation will have proven means to increase adherence through reminder systems, which have shown in past randomized clinical trial to be effective.
The program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretching (cervical extensors and pectoral muscles) exercises based on Harman and Mostafa et al's approach. This exercise program will be repeated 4 times per week for 10 weeks, and each session lasted for 30 minutes.
The goal of the proposed pilot study is to investigate the feasibility and efficacy of the long-acting injectable form of the second generation antipsychotic, risperidone, for the treatment of first episode patients who fail to respond to 12 weeks of treatment with an oral antipsychotic. The rationale for using this long-acting medication is that it eliminates covert non-adherence, which may be a factor in poor response. In addition, pharmacokinetic and pharmacodynamic differences between injectable and oral formulations may result in differences in treatment response favoring the injectable form. Subjects who have not responded sufficiently to treatment with an antipsychotic will be approached for the proposed long-acting risperidone trial. Risperidone treatment will be open label with titration based upon individual response (within FDA approved dose ranges). Treatment will begin with a phase of supplementation with oral risperidone. Subjects will stop their previous antipsychotic, start 2 mg of oral risperidone per day for one day and then increase the dose to 4 mg per day. Subjects who tolerate one week of oral risperidone will then begin injections of 25 mg long-acting risperidone every 2 weeks for a total of 12 weeks. If clinically indicated, the dose may be increased up to a maximum of 50 mg as per FDA guidelines.
Owing to the presence of microbial biofilm on the implant, the eradication of biofilm-associated infections poses a challenge for antibiotic therapies. The study aimed to investigate the efficacy and safety of the novel antibiotic agent TNP-2092 in the context of implant infections. In vivo, rats with periprosthetic joint infection (PJI) treated with antibiotics showed an increase in body weight and decrease in swelling, temperature, and width of knee, compared with the control group. Meanwhile, inflammatory markers in synovium and serum were decreased in the TNP-2092 group, consistent with the pathological results. Moreover, TNP-2092 was effective in eliminating bacteria and disruption biofilm formation, and further alleviated the abnormal bone absorption and reactive bone changes around the prosthesis. In conclusion, intra-articular injection of TNP-2092 is safe and effective in treating knee PJI in a rat model. The study provides a foundation for the future utilization of TNP-2092 in the management of implant-related infections.
Total ankle arthroplasty (TAA) has become a popular management option for ankle arthritis. Periprosthetic osteolysis is one of the most common causes for reoperation in TAA. A CT scan should be done in all suspected osteolysis cases to confirm location, quantify size and aid in surgical planning. These patients are often asymptomatic with limited evidence regarding appropriate management. Smaller lesions should be monitored for progression in size. Periprosthetic cysts measuring 10-15mm in all three axes should be considered for debridment and curettage with autogenous bone grafting. The authors believe that bone grafting of large asymptomatic periprosthetic cysts could prevent implant failure.
PROBLEM TO BE SOLVED: To obtain a controlled release administration composition useful in the administration form for providing controlled release of a medicine having low solubility by a corrosive or diffusing mechanism by making the composition include a specific solid dispersion and a specified cellulose polymer matrix. SOLUTION: This controlled release administration composition comprises (A) a solid dispersion containing a medicine having a low solubility dispersed into a cellulose polymer in which most of the medicine is amorphous and (B) a water-soluble cellulose polymer matrix mixed with the component A in it. The medicine being a medicine having low solubility means a medicine having <=40 mg/ml minimum water solubility at a pathologically related pH (e.g. pH 1-8). An ionic cellulose polymer is preferable as the cellulose polymer of the component A. Methyl cellulose, hydroxyethyl cellulose, etc., may be cited as the water-soluble cellulose polymer.
<P>PROBLEM TO BE SOLVED: To obtain a safe and effective agent for the treatment of periodontosis, an agent for the treatment of endodontosis, a dental material and a denture cleaning agent.  <P>SOLUTION: The agent for the treatment of periodontosis, the agent for the treatment of endodontosis, the dental material and the denture cleaning agent are composed of a liquid bamboo vinegar or a combination of the liquid bamboo vinegar with a salted Ume (Japanese apricot) juice. The agent for the treatment of periodontosis can be used e.g. as a gargle and mouth wash, a liquid dentifrice, a mouth massaging liquid and a dentifrice paste. The agent for the treatment of endodontosis is used e.g. as a root canal sterilizing agent, a plaster, a root canal filler, a point and a pulp capping agent. The dental material can be used e.g. as a primary pit and fissure caries capping agent, a filler and a mounting agent.  <P>COPYRIGHT: (C)2003,JPO
PURPOSE:To obtain a red dyestuff, having improved water solubility and useful for foods, drinks and cosmetics, etc., without toxicity, by enzymically treating a seaweed, e.g. laver, etc. CONSTITUTION:A seaweed, e.g. laver of the genus Porphyra, the family Protoflorideae of the class Rhodophyceae, etc., is dispersed in water and an enzyme, e.g. pancreatin, pronase, cellulase or diastase, or a mixture thereof is added and reacted therewith under given condition of pH and temperature. The reaction mixture is then filtered and freeze-dried.
Palliative oncology providers are ideally situated to improve the cancer journey for the millions of family members and friends who are vital to the care of seriously ill patients. In recent decades, the primary setting for cancer care has shifted from the hospital inpatient unit to the outpatient clinic, leaving family caregivers responsible for providing the majority of patient care in the home, often with little support or preparation. The numerous stressors associated with family caregiving often give rise to caregiver anxiety, depression, fatigue, neglect of self-care and, for particularly strained caregivers, psychological symptoms that mirror those experienced by trauma survivors. In congruence with the National Cancer Institute's commitment to supporting families of individuals with cancer across the full disease trajectory, the investigators seek to examine the feasibility of a technologically-mediated problem-solving intervention designed to improve the quality of life and decrease the psychological distress of family caregivers of cancer patients receiving outpatient palliative care. Specifically, the investigators aim to 1) examine the feasibility of the intervention relative to recruitment, randomization, retention, and fidelity to core intervention components; 2) investigate the impact of the intervention on family caregiver anxiety, depression, and quality of life; and 3) explore the benefits and challenges associated with the intervention from the perspective of participants. To accomplish these aims, investigators will recruit and randomly assign 82 family caregivers of cancer patients receiving outpatient palliative care into two groups (usual care and intervention) and collect quantitative and qualitative data, which will be analyzed to inform a future large-scale randomized clinical trial of the problem-solving intervention.
Ensuring the safety and comfort of the more than 100,000 critically ill infants and young children supported on mechanical ventilation in the US each year is integral to the practice of pediatric critical care. Humane care of these young patients requires the use of sedating medications, most commonly combinations of opioids and benzodiazepines. Unfortunately, sedative use also carries risk. Animal studies found that even transient administration of benzodiazepines and other sedatives during periods of developmental synaptogenesis caused widespread neuronal apoptosis and residual learning and memory deficits. Sedation is administered for days to weeks in \>90% of acutely-ill, ventilated infants and children. Thus, a commonly used treatment in critically ill young children may itself have detrimental, age-dependent long-term effects.

An opportunity to increase the understanding of the long-term cognitive effects of sedation during critical illness in children has been provided by the cluster randomized, controlled trial of a sedation protocol, Randomized Evaluation of Sedation Titration for Respiratory Failure (RESTORE), U01 HL086622, PI Curley, 31 sites, n=2,816. This trial determined whether the trial's sedation protocol used at intervention sites decreased the duration of mechanical ventilation and sedative exposure among children with acute respiratory failure due to a primary pulmonary process. Control sites continued usual sedation practice. We collected detailed data on doses and durations of sedative medications, in-hospital course, and post-discharge quality of life.

The purpose of RESTORE-cognition is to determine the relationships between sedative exposure during pediatric critical illness and long-term neurocognitive outcomes. We will assess multiple domains of neurocognitive function 2.5-5 years post-discharge in 500 RESTORE subjects with normal baseline cognitive function aged 2 weeks to 8 years at pediatric intensive care unit admission. In addition, we will study 310 matched, healthy siblings of RESTORE subjects to provide data on an unexposed group with similar baseline biological characteristics and environment. Our goal is to increase our understanding of the relationships between sedative exposure, critical illness, and long-term neurocognitive outcomes in infants and young children.
A hydroalcoholic gel acts as a carrier system for bioactive substrates. This hydroalcoholic gel contains water and lower alcohol as the continuous phase. It also contains gelling agents, thickening agents, skin conditioning agents, emulsifiers, and penetration enhancers. This hydroalcoholic gel can be manufactured through a process that does not require external heating.  This hydroalcoholic gel can self-emulsify into a lotion or cream texture when an oil is introduced to the system. Bioactive substrates that can be incorporated into this carrier hydroalcoholic gel can be hydrophilic or hydrophobic. Hydrophilic bioactive substrates can be dispersed into the gel directly, while hydrophobic substrates can be incorporated firstly into an oil and then into the carrier gel through a self-emulsification process. This hydroalcoholic gel can enhance the topical delivery efficacy of certain substrates.
INTRODUCTION: Pelvic floor disorders (PFD) occur in about 40% of women after delivery. Less is known about the intervention and care needs of women with postpartum PFD. The aim of this analysis was to analyze care needs and self-initiated measures to strengthen the pelvic floor in postpartum women in relation to incontinence and sexual dysfunction. Furthermore, influencing factors for self-initiated measures were evaluated.
PATIENTS AND METHODS: An anonymous online survey (via LimeSurvey) was conducted between September and October 2022 and distributed via social media (Instagram and Facebook). The survey explicitly addressed mothers with and without pelvic floor disorders up to 5 years postpartum (inclusion criteria). Validated instruments were employed to assess incontinence (ICIQ-SF) and sexual functioning (PISQ-IR: Condition Impact). The questions on the use of services and preventive measures, as well as on the interaction with a gynecologist, were based on self-developed items.
RESULTS: In total, 49.4% of the participants of the survey showed symptoms of urinary incontinence (UI). Furthermore, only 40.3% (n = 241) of women were actively asked by their gynecologists for the occurrence of UI or PFD among those who suffered from PFD. Overall, 79.3% of the participants of the survey with UI underwent measures to deal with the complaints. The ICIQ-SF Score was significantly associated with all self-induced measures. High School diplomas and academic degrees were associated with the use of love balls (p < 0.05).
CONCLUSION: The results of the study show the unmet needs of postpartum women. PFD should be addressed more frequently in the outpatient setting. Furthermore, more systematic information about the treatment of PFD could help to address unmet information needs and improve interventions.
The efficacy of AXERT® in adolescent patients age 12 to 17 years was evaluated in a double-blind, randomized, placebo-controlled study. Patients enrolled in that study had at least a 1-year history of migraine attacks with or without aura usually lasting 4 hours or more (when untreated). Patients enrolled in the study were primarily females (60%) and Caucasian (75%), while 15% of patients were black, and 10% were of other races. Patients were instructed to treat a moderate to severe migraine headache. Two hours after taking one dose of study medication, patients evaluated their headache pain. Associated symptoms of nausea, photophobia, and phonophobia were also evaluated.

In this study, the percentage of patients achieving a pain relief response (mild or no pain) 2 hours after treatment was statistically significantly greater in patients who received AXERT® 6.25 mg or 12.5 mg compared with those who received placebo. There was no additional benefit on pain relief provided by the 12.5 mg dose. The 2-hour pain relief results are summarized in Table 4.

The estimated probability of achieving pain relief within 2 hours following initial treatment with AXERT® in adolescents age 12 to 17 years is shown in Figure 3.

The prevalence of the migraine-associated symptoms (nausea, photophobia, and phonophobia) at 2 hours after taking the dose was not significantly different between patients who received AXERT® 6.25 mg or 12.5 mg and those who received placebo.
BACKGROUND: We investigated (a) whether polygenic risk for schizophrenia predicts different trajectories of social development among those who have not developed psychoses and (b) whether possible associations are PRSSCZ-specific or evident also for any polygenic risk for mental disorders, e.g. for major depression.
METHODS: Participants came from the population-based Young Finns Study (n = 2377). We calculated a polygenic risk score for schizophrenia (PRSSCZ) and for major depression (PRSDEP). Diagnoses of psychotic disorders were derived from the hospital care register. Social development from adolescence to middle age was measured by (a) perceived social support from friends, family, and a close other, (b) perceived sociability, and (c) family structure (partnership status, number of children, age of first-time parenthood).
RESULTS: Among those without manifest psychoses, high PRSSCZ predicted lower experienced support from friends (B = -0.04, p = 0.009-0.035) and family (B = -0.04, p = 0.009-0.035) especially after early adulthood, and also lower perceived sociability (B = -0.05, p = 0.010-0.026). PRSSCZ was not related to family structure. PRSDEP did not predict any domain of social development.
CONCLUSIONS: Individuals at high PRSSCZ (not converted to psychosis) seem to experience a lower preference to be with others over being alone. Individuals with high (v. low) PRSSCZ seem to have a similar family structure in terms of partnership status or number of children but, nevertheless, they experience less support from their family. Among those not converted to psychosis in a typical age period, high PRSSCZ may predict a 'later risk phase' and reduced functional resilience when approaching middle age.
The present invention relates to a group of recombinant proteins (generally referred to in the present document as HA 50-274 -H1N1) which can be expressed in  E. coli , which contain a hemagglutinin (HA) fragment of the H1N1/2009 influenza A virus in the sequence thereof and which exhibit immunogenic and protective activity against influenza infection in mammals. This fragment corresponds to the region between amino acid 50 and amino acid 274 of H1N1/2009 influenza A virus hemagglutinin (SEQ ID No. 1). The invention also relates to a plurality of clones capable of expressing said group of immunogenic and protective proteins, for example clones such as  E. coli  BL21 (DE3) pLysS C41 deposited at the ATCC ®  under patent deposit designation PTA-10320. The invention further relates to the use of said proteins as vaccines or ingredients in formulations for vaccines against H1N1/2009 influenza A infection or seasonal influenza infection. In addition, the invention relates to a method whereby HA 50-274 -H1N1 protein variants can be produced with a suitable level of biological activity (specific recognition of human serum antibodies in patients convalescing from H1N1/2009 influenza A, specific immunogenic activity in mammals, protective activity in mammalian cell cultures and animal models) and a sufficient level of purity for industrial use.